AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03866421 — intervention group
Intervention type: RADIATION
Intervention: Dual Energy X-ray Absorptiometry (DEXA) scan
Description: DEXA-scan of the body composition.
Study NCT03866421 — intervention group
Intervention type: BIOLOGICAL
Intervention: Blood samples
Description: Immediately analyse of basic lab data. Later analyses for glucagon, amino acids, bile acids, lipidomics and metabolomics.
Study NCT03866421 — intervention group
Intervention type: OTHER
Intervention: Clinical and demographic data
Description: Measurements of blood pressure, pulse, height, weight.
Study NCT04199377 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HIP KNEE REPLACEMENT
Description: HIP KNEE REPLACEMENT
Study NCT00330694 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ParkNet
Description: Development of a network of dedicated physiotherapist with specific expertise in Parkinson's Disease and structured referrals to these ParkNet therapists by neurologists.
Study NCT00330694 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Usual Care
Description: No altered organisation of physiotherapy care in Parkinson's Disease
Study NCT03591601 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual Therapy protocol
Description: Treatment based on manual therapy with proven evidence.
Study NCT03591601 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Foam Rolling protocol
Description: Treatment based on massage with a Foam Rolling
Study NCT03591601 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo control
Description: Placebo treatment based on the placement of the hands on the head without intention to treat.
Study NCT03000985 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Description: 6 session psychoeducation program with the family caregiver of schizophrenics patients.
Study NCT02169505 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Starting dose: 1.2 mg/kg by vein on Day 1 for the first 2, 21 day cycles. Dose increased to 1.8 mg/kg by vein after the second cycle for all subsequent cycles.
Study NCT00613366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol
Description: Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
Study NCT00613366 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium Oxide
Description: Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
Study NCT00130689 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Cetuximab
Study NCT02235181 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Arabin Cervical Pessary
Description: The Arabin pessary is CE-certified for preventing Spontaneous Preterm Birth (SPB) (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC) and is being used in this study as per the CE certification and manufacturer's guidance.
Study NCT03583879 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exoskeleton exercise
Description: Functional exercise with a robotic exoskeleton
Study NCT03583879 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard exercise
Description: Functional exercise without a robotic exoskeleton
Study NCT03583879 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No treatment
Description: Wait-list control
Study NCT06371690 — intervention group
Intervention type: OTHER
Intervention: Web-Based Double-Eye Control Program
Description: Web-Based Double-Eye Control Program, a web-based drug dose calculation program, is compatible with smartphones, tablets and computers. On the interface of the website, the nurse is required to enter data such as the age, weight, medications and doses ordered by the physician of the patient. When all these data are entered, the amount of medication that the nurse should give and whether the ordered dose is within the safe dose range for the patient are calculated by the program, so that the nurse can control her own calculations. On the other interface of the website, there are medication instructions uploaded by the researchers. With this interface, nurses access all pharmacological information about especially high-risk drugs (indications, contraindications, interacting drugs and fluids, fluids to be used for diluting, medication route, medication pace, etc.) and information that will enable the medication to be carried out in a standard way.
Study NCT04563754 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: mHRME (Mobile High resolution microendoscope)
Description: Standard of care (SOC) high-resolution anoscopy (HRA) with Lugol's iodine will be performed. The unstained (abnormal) area will be evaluated with mHRME for optical biopsy diagnosis:~1. contrast agent will be applied to anal epithelium (5-10 ml of proflavine hemisulfate (0.01%)),~2. the mHRME will then be inserted and imaging of abnormal tissues will be performed. This will add 2 to 6 minutes per procedure.~This is a single-arm study where all subjects will receive both SOC HRA and experimental mHRME imaging.
Study NCT04563754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proflavine Hemisulfate
Description: Contrast agent will be applied to anal epithelium (5-10 ml of proflavine hemisulfate (0.01%)) to use with the mHRME
Study NCT04563754 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High resolution anoscopy
Description: Standard of care (SOC) HRA with Lugol's iodine will be performed.
Study NCT03042351 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Magic Kegel app
Description: Pelvic floor muscles recover exercises with a specific device and Magic Kegel App
Study NCT01865721 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entonox
Description: Entonox will be used according to the allocated method
Study NCT03444805 — intervention group
Intervention type: PROCEDURE
Intervention: Autologous HSCT
Description: 1st AHSCT
Study NCT02035553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pimavanserin tartrate
Description: Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)
Study NCT02035553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, two tablets, once daily by mouth
Study NCT01678118 — intervention group
Intervention type: BEHAVIORAL
Intervention: Patient Navigator
Description: The pt navigator will phone (email, text, or other preferred method of contact) pts prior to the date of previously set individual goals (e.g. going to an appt, getting their cessation medications filled, etc) as a reminder \& to discuss barriers such as finances, transportation or ambivalent motivation. In this manner, pts receive navigation services tailored to their individual needs \& barriers. Once pts are connected with a cessation service (defined as either using cessation medication or at least 1 contact with a Quitline or community-based cessation counselor)or provider-prescribed cessation medication usage, continues the navigation intervention will be considered complete. W/I the 3 month engagement period, pts will receive up to 6 contacts from the Pt Navigator following referral from primary care provider. Consistent with recommended pt navigation practice, the navigator will provide feedback to primary care provider regarding cessation services that the pts are receiving.
Study NCT03868839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan Pill
Description: telmisartan 40mg once a day during week 1; the dose will be increased to 80mg (target dose) or as tolerated during the remaining three weeks.
Study NCT04227418 — intervention group
Intervention type: DEVICE
Intervention: 12 lead ECG monitoring
Description: Rate, Rhythm, QTc and PR interval will be assessed
Study NCT04227418 — intervention group
Intervention type: DEVICE
Intervention: 6 lead ECG monitoring
Description: Rate, Rhythm, QTc and PR interval will be assessed
Study NCT04227418 — intervention group
Intervention type: DEVICE
Intervention: Hand held ECG monitoring
Description: Handheld ECG machines are portable, inexpensive, hand held devices that provide a 'real-time' rhythm strip, equivalent to lead I or II on a 12 lead machine, depending on how the device is held. The rhythm strip is displayed on a computer tablet or mobile phone, and are compatible with both android and iPhone platforms. To perform the test the patient places their fingers/thigh, or alternatively the device can be placed directly on the patient's chest. The process does not require the patient to be exposed, can be done in a seated position (negating the need an examination couch) and their ease of use and portability means they could be readily used in memory clinics or community settings.
Study NCT01178125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DR-102
Study NCT03795337 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Hypofractionated Radiosurgery
Description: Image-guided stereotactic Linac based RT preferable with dedicated radiosurgery system such as CyberKnife
Study NCT00094679 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Eye patch
Description: adhesive patch to cover the sound eye
Study NCT01674465 — intervention group
Intervention type: BIOLOGICAL
Intervention: Hypoxyprobe-1
Description: Hypoxyprobe-1 is a biological marker used to detect oxygen levels in tissue;subjects will receive and intravenous solution for 20 minutes containing 500mg/m\^2 two-three hours prior to their standard of care biopsy
Study NCT03677115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: combination of ropivacaine and dexmedetomidine 20 ug every time
Study NCT01711983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GORE® CARDIOFORM Septal Occluder
Description: Percutaneous Atrial Septal Defect Closure
Study NCT04820322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fibersym
Description: RS4-type resistant modified wheat starch
Study NCT04820322 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control cookie
Description: control cookie
Study NCT04414475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Participants will receive Selinexor oral tablets.
Study NCT04414475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Participants will receive Dexamethasone oral tablets.
Study NCT04348097 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activator instrument
Description: activator instrument was placed perpendicular over the identified trigger point and 10 thrusts were delivered, with a rate of one thrust per second
Study NCT04348097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Activator instrument
Description: activator instrument was placed perpendicular over the identified trigger point and 10 thrusts were delivered, with a rate of one thrust per second
Study NCT04414475 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Participants will receive Bortezomib SC injection.
Study NCT04348097 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: dry needle
Description: By wrist flexion and extension movements, the trigger point was needled in different directions and tried to elicit at least one local twitch response during the procedure and patient's familiar referral pain was tried to obtain . Each dry needling procedure lasted 1-2 minutes
Study NCT04348097 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dry needle
Description: By wrist flexion and extension movements, the trigger point was needled in different directions and tried to elicit at least one local twitch response during the procedure and patient's familiar referral pain was tried to obtain . Each dry needling procedure lasted 1-2 minutes
Study NCT01433419 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-875
Study NCT03555422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
Study NCT03555422 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo for selinexor
Description: Dose: 80 mg (4 tablets) or 60 mg (3 tablets); Dosage form: film-coated, immediate-release tablet of 20 mg each; Route of administration: oral
Study NCT01788319 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: lasertrabeculoplasty
Study NCT00270296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trizivir
Description: 300 mg abacavir sulfate/150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
Study NCT00270296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine/Zidovudine
Description: 150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
Study NCT00270296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lopinavir/Ritonavir
Description: 400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily
Study NCT00270296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nevirapine
Description: 200 mg tablet taken orally daily for the first 14 days before receiving 200 mg tablet taken orally twice daily
Study NCT04884646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR with Routine physical therapy and Virtual reality
Description: VR group will be treated with virtual reality for 15 to 20 minutes along with routine physical therapy for 40 minutes session 3 days/week for 12 weeks
Study NCT04884646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery with Routine physical therapy
Description: MI group will be treated with virtual reality for 15 to 20 minutes along with routine physical therapy for 40 minutes session 3 days/week for 12 weeks
Study NCT04884646 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Routine physical therapy
Description: Group A will be given routine physical therapy in 40-min sessions and 20 min of walking and cycling with a short period of rest, every alternate day (3 days per week) for 12 weeks
Study NCT01153607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1006578
Description: Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
Study NCT01153607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1006578
Description: Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
Study NCT01153607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY1006578
Description: Healthy volunteers for whole body imaging: Single intravenous bolus injection of 190 MBq BAY1006578, whole body PET for evaluation of effective dose, kinetics of BAY1006578 in blood
Study NCT03629145 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Live Music Therapy
Description: Investigator will begin play live guitar and voice music.
Study NCT03629145 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Recorded Music Therapy
Description: Investigator will play recorded music.
Study NCT03866356 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention group
Description: The women in the intervention group were provided care according to SICP
Study NCT02309970 — intervention group
Intervention type: DRUG
Intervention: acetylsalicylic acid, clopidogrel bisulfate and/or warfarin, Apixaban, Rivaroxaban, Dabigatran
Description: subject in this group will receive oral treatment with anti platelet drug
Study NCT02309970 — intervention group
Intervention type: DRUG
Intervention: alteplase
Description: subject in this group will receive intravenous tPA
Study NCT02309970 — intervention group
Intervention type: PROCEDURE
Intervention: endovascular
Study NCT01908712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamazym
Description: ERT, i.v. infusions weekly
Study NCT01787669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin (Bevacizumab)
Description: Avastin (Bevacizumab) administered intravitreally
Study NCT01787669 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ozurdex (dexamethasone)
Description: Ozurdex (dexamethasone) given intravitreally
Study NCT01161576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies
Description: The experimental drug for this second generation study has a genome identical to that used in our previous study and delivers the same gene, but instead of an AAV2 capsid (protein shell of the virus), the new vector has the capsid of AAVrh.10, a clade E AAV derived from rhesus macaque (a species of Old World monkeys). The first dose that was given to the first 6 subjects is 9.0x10\^11(900,000,000,000 molecules of the drug) genome copies/subject. In regards to drug administrations, we propose to perform 2 series of 6 simultaneous administrations of vector for 75 min each. Each subject will receive the assigned dose of AAVrh.10CUhCLN2, divided among 12 locations delivered through 6 burr holes (2 locations at 2 depths through each hole), 3 burr holes per hemisphere.
Study NCT01161576 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies
Description: The experimental drug for this 2nd generation study has a genome identical to that used in our previous study and delivers the same gene but instead of an AAV2 capsid (protein shell of the virus), the new vector has the capsid of AAVrh.10, a clade E AAV derived from rhesus macaque (a species of Old World monkeys). Group B will receive a dose of 2.85x10\^11 genome copies (285,000,000,000 molecules of the drug). In regards to drug administration, we propose to perform 2 series of 6 simultaneous administrations of vector for 75 min each. Each subject will receive the assigned dose of AAVrh.10CUhCLN2, divided among 12 locations delivered through 6 burr holes, 3 burr holes per hemisphere.
Study NCT00848757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intensive Lifestyle Intervention
Description: Women with pre-diabetes randomized to the ILI will attend an intensive 12-week group program of nutritional education, diet, behavior modification and structured exercise, which is based on the published curriculum from the DPP Lifestyle Balance program, but modified for a group format and to be more culturally and linguistically appropriate for this population.
Study NCT02257528 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01726075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COLIRIOBCN070660
Description: One drop per eye twice a day during 24 months
Study NCT01726075 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One drop per eye twice a day during 24 months
Study NCT01726075 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine
Description: One drop per eye twice a day during 24 months
Study NCT02761018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Fitness Tracker
Description: will use a fitness tracker but will not be able to see other participant's data
Study NCT02761018 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitness Tracker
Description: will use a fitness tracker and will be able to see other member's daily and weekly results
Study NCT03576339 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Free Gingival Graft
Description: Free gingival graft removal from palate for socket preservation
Study NCT03576339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Free Gingival Graft
Description: Free gingival graft removal from palate for socket preservation
Study NCT03576339 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM Electric stimulation
Description: Simulation of electric stimulation protocol for 120 seconds once a day in five consecutive days. In Sham stimulation non current will be applied.
Study NCT03576339 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electric Stimulation
Description: Local Electric Stimulation for 120 seconds once a day in five consecutive days.
Study NCT05304988 — intervention group
Intervention type: OTHER
Intervention: Testing of the EFT
Description: A research committee which composes of a paediatric oncologist, a ward manager, an assistant professor and a research assistant will be set up. The committee will develop specific questions in EFT and design and implement the clinical Then, subject will be invited to fill in a set of questionnaires covering demographic characteristics, EFT items and a numerical rating scale for pain scores. The oncologist will rate the subject with the most appropriate level of physical activity on a 4-point scale.
Study NCT01100723 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cinacalcet, active vitamin D analogue
Description: Patients will have their mineral and bone disorders managed by the computer directed algorithm. Cinacalcet will be dose increased starting at 30 mg/day as indicated by protocol along with active vitamin D based on values of serum calcium, phosphorus and parathyroid hormone.
Study NCT06069739 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guided physical activity
Description: To achieve the European guidelines of 150 minutes by week of moderate intensity physical activity, participants randomized to the GPAG condition were prescribed three 60 minutes exercise sessions (five minutes of warm-up and five minutes of cool-down for a total of sixty minutes per session) per week for 12 weeks. Exercise consisted of brisk walking in urban and rural open spaces during which heart rate monitors were worn and participants were instructed to stay within their moderate intensity range. The incentives were different proposals for specific exercises to train the different musculoskeletal areas more comprehensively. Autonomous exercise was monitored offside the sessions through a series of weekly checkpoints.